Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 419-426 , May 2009

Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model

  • Myungmi Oh

      Affiliations

    • Department of Otorhinolaryngology, School of Medicine, University of Fukui, Matsuoka Shimoizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
    • ,
  • Takeshi Tanaka

      Affiliations

    • Department of Otorhinolaryngology, School of Medicine, University of Fukui, Matsuoka Shimoizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
    • ,
  • Masato Kobayashi

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Matsuoka Shimoizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
    • ,
  • Takako Furukawa

      Affiliations

    • Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Anagawa 4-9-1, Chiba 263-8555, Japan
    • ,
  • Tetsuya Mori

      Affiliations

    • Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Takashi Kudo

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Matsuoka Shimoizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
    • ,
  • Shigeharu Fujieda

      Affiliations

    • Department of Otorhinolaryngology, School of Medicine, University of Fukui, Matsuoka Shimoizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
    • ,
  • Yasuhisa Fujibayashi

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Matsuoka Shimoizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 776 61 8431; fax: +81 776 61 8170.

Received 14 October 2008 ,Revised 26 December 2008 ,Accepted 31 January 2009.

References 

  1. Hammer S, To KK, Yoo YG, Koshiji M, Huang LE. Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle. 2007;6:1919–1926
  2. Wouters A, Pauwels B, Lardon F, Vermorken JB. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist. 2007;12:690–712
  3. Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323–328
  4. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177–183
  5. Fujibayashi Y, Cutler CS, Anderson CJ, McCarthy DW, Jones LA, Sharp T, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol. 1999;26:117–121
  6. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–1160
  7. Obata A, Kasamatsu S, Lewis JS, Furukawa T, Takamatsu S, Toyohara J, et al. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nucl Med Biol. 2005;32:21–28
  8. Lewis J, Laforest R, Buettner T, Song S, Fujibayashi Y, Connett J, et al. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci USA. 2001;98:1206–1211
  9. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–1238
  10. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182
  11. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol. 2006;33:743–750
  12. Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, et al. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nucl Med Biol. 2003;30:529–534
  13. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–1502
  14. Matsumoto K, Szajek L, Krishna MC, Cook JA, Seidel J, Grimes K, et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 2007;30:873–881
  15. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–322
  16. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–238
  17. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science. 1982;218:414–415
  18. Riccardi A, Danova M, Ascari E. Bromodeoxyuridine for cell kinetic investigations in humans. Haematologica. 1988;73:423–430
  19. Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, Van Der Kogel AJ. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys. 2000;48:1529–1538
  20. Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499–504
  21. Moreno SN, Mason RP, Muniz RP, Cruz FS, Docampo R. Generation of free radicals from metronidazole and other nitroimidazoles by Tritrichomonas foetus. J Biol Chem. 1983;258:4051–4054
  22. Arteel GE, Thurman RG, Yates JM, Raleigh JA. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer. 1995;72:889–895
  23. Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem. 1998;253:743–750
  24. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–7220
  25. van Dierendonck JH, Keijzer R, van de Velde CJ, Cornelisse CJ. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res. 1989;49:2999–3006
  26. Du Manoir S, Guillaud P, Camus E, Seigneurin D, Brugal G. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry. 1991;12:455–463
  27. Green SL, Freiberg RA, Giaccia AJ. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol. 2001;21:1196–1206
  28. Denko NC, Green SL, Edwards D, Giaccia AJ. p53 checkpoint-defective cells are sensitive to X rays, but not hypoxia. Exp Cell Res. 2000;258:82–91

PII: S0969-8051(09)00040-7

doi: 10.1016/j.nucmedbio.2009.01.016

Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 419-426 , May 2009

Article Tools

* Image Usage & Resolution